Clinical Trial Update: Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) [Phase 3]

View source ↗

Summary

Phase 3 study of pomalidomide and low-dose dexamethasone with or without pembrolizumab in relapsed/refractory multiple myeloma was terminated; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dexamethasone (low-dose) (dexamethasone)
• Pembrolizumab (pembrolizumab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Multiple Myeloma | Phase 3 | Status: TERMINATED | Results posted: 2019-08-02